Hitgen Ltd., of Chengdu, China, said it forged a license agreement with Kaken Pharmaceutical Co. Ltd., of Tokyo, to develop a class of drugs for an undisclosed target nominated by Kaken. The small-molecule leads were identified by Hitgen's screening technology platform.